Effect of administration of atosiban at day of embryo transfer on in-vitro fertilization out come

Abstract

Background: The most crucial step of assisted reproduction is embryo implantation, which is impacted by a variety of factors, including the patient's age, embryo quality, and endometrial receptivity. The embryo transfer (ET) procedure, which induces uterine contractions, may hinder embryo implantation. Objectives: On the day of embryo transfer, examine the effects of Atosiban administration on implantation, clinical pregnancy, miscarriage, and live birth rates. Material and Methods: The study included 60 individuals with a diagnosis of primary or secondary infertility due to male or female factor, tubal factors, moderate endometriosis, or other unknown reasons. Two groups of patients were selected at random. The first group received 6.75 milligrammes of atosiban intravenously 30 minutes before ET, whereas the second group received no medication. Pregnancy outcomes in both groups were compared. Results: Significantly higher clinical pregnancy and implantation rates were observed (60% versus 30%) and (37.8% versus 17.8%) respectively, with non-significantly higher live birth rates (94.4% versus 66.7%), while the miscarriage rate was lower in the Atosiban group but not significantly (5.6% versus 33.3%). Conclusion: These findings imply that atosiban therapy prior to embryo transfer improves embryo implantation.